Highest development stage: Phase 3 (NCT04979806)

Development status: Active (as of 2024)

Gram-negative activity

Combination therapy

Mechanism of Action/Target pathogen: Active against <i>Enterobacteriaceae</i>, <i>Pseudomonas aeruginosa</i>, and <i>Acinetobacter baumannii</i>; indicated for complicated urinary tract infections hospital-acquired bacterial pneumonia/ ventilator-associated bacterial pneumonia, complicated intraabdominal infections, and bacteremia